Shionogi Buys Global RADICAVA Rights in $2.5 Billion ALS Drug Deal to Build Rare Disease Platform

An announcement from Shionogi & Co ( (JP:4507) ) is now available.

Shionogi has agreed to acquire from Tanabe Pharma the global rights and assets for RADICAVA ORS (edaravone) and IV RADICAVA, key treatments for amyotrophic lateral sclerosis, by purchasing 100% of a new Tanabe entity that will hold the business, including a U.S. subsidiary that will become wholly owned by Shionogi Inc. The USD 2.5 billion deal, expected to close on or after April 1, 2026 and to be accretive from FY26 with around USD 700 million in annual global sales, will establish a dedicated rare disease commercial platform in the U.S., integrate specialized talent, and provide infrastructure to accelerate commercialisation of Shionogi’s broader rare disease pipeline while having minimal impact on results for the fiscal year ending March 31, 2026.

The most recent analyst rating on (JP:4507) stock is a Buy with a Yen3015.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.

More about Shionogi & Co

Shionogi & Co. is a Japan-based pharmaceutical company focusing on developing and commercializing innovative medicines, with a growing strategic emphasis on high social impact quality-of-life disorders such as sleep disorders, hearing loss and rare diseases. The company is building a rare disease portfolio that includes programs in Fragile X syndrome, Jordan’s syndrome and Pompe disease, and is seeking to expand its U.S. commercial infrastructure to support future launches in these specialized therapeutic areas.

YTD Price Performance: 25.72%

Average Trading Volume: 2,760,066

Technical Sentiment Signal: Buy

Current Market Cap: Yen2388.8B

See more data about 4507 stock on TipRanks’ Stock Analysis page.